Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients

Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing. Roughly [5,000 new cases]( are diagnosed each year in the United States — and once diagnosed, patients have a life expectancy of just three to five years. With so many questions still unanswered about the causes of the disease, drug developers have struggled to create treatments that offer much relief for these patients. Pasithea Therapeutics Corp., a developmental-stage biotech, says it is hoping to bring new hope to those suffering from ALS with the recent addition of a novel drug candidate to its pipeline. What Is Amyotrophic Lateral Sclerosis? ALS is a progressive neurodegenerative disease that causes nerve cells throughout the body to stop working and die. Without those nerve cells, the body loses the ability to trigger voluntary muscle movements, starting with mild weakness or stiffness and eventually leading to paralysis. For the roughly [25,000 Americans]( suffering from the disease, that means they will progressively lose the ability to speak, eat, move and even breathe without the assistance of machines. What makes the debilitating disease even more troubling is that it’s so hard to predict who will get it. While being the offspring of a parent with ALS puts you at high risk of developing it yourself, about [90% of cases]( have no known family history of the disease. So, it’s not strictly genetic. Research into environmental risk factors — like exposure to toxins or poor diet and lifestyle — has also yielded few answers. While some data suggests military veterans are [twice as likely]( to be diagnosed than the general public — and men slightly more likely than women — it’s still not known why or what factors may be at play. One clue researchers have is the age of onset. Symptoms typically appear between the ages of 55 and 75, which suggests that it might be an age-related disease. The Limited Treatment Options for ALS Patients With so little understanding of the causes, developing treatments for the disease has been reportedly challenging. Two drugs that have been approved by the Food and Drug Administration (FDA) for ALS so far are Rilutek, sold by Sanofi SA and Radicava, manufactured by Mitsubishi Tanabe Pharma America Inc. The most effective is Rilutek, known as Riluzole in generic form, which works by [blocking]( the release of glutamic acid into the central nervous system. Because toxic levels of glutamate may be linked to ALS, blocking glutamic acid is thought to keep those levels closer to normal. But even with it being the most effective drug so far, it can only prolong tracheostomy-free survival — living without a surgically implanted breathing tube — by [about two to three months]( on average. The mechanism of action for Radicava, or Edaravone, is [less clear, but it may be providing antioxidants]( that protect against damage and death in all cells, including the nerve cells that are dying at rapid rates in ALS patients. While some data shows that the antioxidant may improve symptoms over the short term, it doesn’t prolong survival at all. Pasithea Reports Targeting Inflammation in Hopes of Slowing ALS Disease Progression Pasithea says it is hoping to change that dismal treatment landscape with its latest drug candidate. Recently acquired as part of the [acquisition of Alpha-5 integrin LLC]( the company is developing a monoclonal antibody for the treatment of ALS and other neuroinflammatory disorders by blocking the Alpha-5/Beta-1 integrin. [Integrins]( are a kind of receptor on the surface of the cell. They can bind to other structures, trigger cell migration and activate processes like cell growth and reproduction. The Alpha-5/Beta-1 integrin, or fibronectin receptor, that Pasithea is targeting is specifically responsible for regulating several neuroinflammatory cells. By blocking the expression of this particular integrin, this novel drug aims to reduce neuroinflammation, which would then hopefully slow the rate of damage and death of motor neurons. Inflammation has become a focus of some ALS research because the immune response can cause serious damage if prolonged or over-activated. Its main role in the body is to target and destroy infected cells and harmful foreign substances — but its lethal powers can leave no shortage of casualties in its wake. The damage from chronic or frequent inflammation builds up over time, which has made it the focus of research on many age-related or progressive diseases like Alzheimer’s disease and multiple sclerosis. Because ALS may be an age-related disease and because its symptoms are linked to the progressive death of nerve cells, targeting inflammation to reduce cell damage and death may help slow the progression of the debilitating disease. With the new acquisition, Pasithea is planning to move this drug into ALS clinical trials as soon as possible. “Our plan is to file an Alpha-5 investigational new drug application (IND) with an orphan drug designation by the end of 2023,” Dr. Tiago Reis Marques, CEO of Pasithea, said in a [statement]( on the acquisition. This website is wholly owned by tradigital marketing group, inc. (d/b/a “tradigital ir”). Our reports are advertorials and are for general information purposes only. never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. please note well: tradigital ir and its employees are not registered investment advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold tradigital ir, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. tradigital ir encourages readers and investors to supplement the information in these reports with independent research and other professional advice. all information on featured companies is provided by the companies profiled or is available from public sources and tradigital ir makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. none of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. instead, tradigital ir strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. tradigital ir’s full disclosure is to be read and fully understood before using tradigital ir's website, or joining tradigital ir's email or text list. From time to time, tradigital ir will disseminate information about a company via website, email, sms, and other points of media. by viewing tradigital ir's website and/or reading tradigital ir's email or text newsletter you are agreeing ----> . all potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation. in compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between tradigital and pasithea therapeutics corp. tradigital was hired for a period beginning january 2022 and ending march 2022 to publicly disseminate information about pasithea therapeutics corp. via website, email, and sms. We were paid three hundred ninety-four thousand usd via ach. Subsequently, we were paid four hundred ninety-nine thousand usd via ach to publicly disseminate information about pasithea therapeutics corp. via website, email, and sms. We own one hundred fifty thousand restricted common shares of pasithea therapeutics corp., which are eligible for sale on 03/18/2022. For the purpose of this disclaimer, we suggest that you assume we will sell all of our shares once the restriction is lifted on 03/18/2022. Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. tradigital ir is compliant with the can-spam act of 2003. tradigital ir does not offer investment advice or analysis, and tradigital ir further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, tradigital ir has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, tradigital ir and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. tradigital ir is not responsible for any claims made by the companies advertised herein, nor is tradigital ir responsible for any other promotional firm, its program, or its structure. tradigital ir is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra. No longer want to receive these emails? [Unsubscribe](. TradigitalIR 12 E 49th Street, 11th Fl. New York, NY 10017 ‌